Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 2/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATP4A | P20648 | 1/20 | 0.39 |
| ▸ | ATP4B | P51164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2860108 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL30122456 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL7080293 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL24715737 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL1520704 | 0.80 | PDE10A (0.47) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL2709144 | 0.77 | TNKS (0.44) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL13135655 | 0.75 | EZH2 (0.57) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL2857372 | 0.74 | NCF1 (0.49) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL3952773 | 0.74 | TNKS (0.47) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL24715740 | 0.74 | HTR1A (0.55) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| CN-100341862-C | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORP (JP) | 2007-10-10 | — | — | CN | disclosed |
| CN-1606549-A | Thiazolidine derivative and medical application thereof | MITSUBISHI PHARMA CORP (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | KDM4E 1080/4885ALDH1A1 148/4885HPGD 2029/4885 |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | DPP4, DPP7, DPP3 | KDM4E 1384/4885ALDH1A1 31/4885HPGD 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.